Christenssenella Minuta a Novel Live Biotherapy for Obesity and Metabolic Diseases

Time: 1:50 pm
day: Track A - Evening - Day One


• Preclinical proof of concept of novel selected C. minuta clinical candidate strain, Xla1, for the
treatment of obesity and metabolic diseases
• Topline data Phase1 clinical study assessing Xla1 in healthy and obese volunteers
• C. minuta therapeutic potential beyond obesity